Concepts (123)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Irritable Bowel Syndrome | 2 | 2012 | 13 | 0.460 |
Why?
|
| Gastrointestinal Agents | 2 | 2012 | 31 | 0.450 |
Why?
|
| Vascular Malformations | 1 | 2012 | 20 | 0.400 |
Why?
|
| Hemangioma | 1 | 2012 | 28 | 0.400 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2012 | 132 | 0.390 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2012 | 181 | 0.370 |
Why?
|
| Interleukin-10 Receptor alpha Subunit | 1 | 2010 | 1 | 0.360 |
Why?
|
| Drugs, Investigational | 1 | 2010 | 11 | 0.360 |
Why?
|
| Alleles | 1 | 2010 | 424 | 0.320 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2010 | 106 | 0.320 |
Why?
|
| Proton Pump Inhibitors | 2 | 2013 | 40 | 0.210 |
Why?
|
| Urothelium | 1 | 2019 | 22 | 0.170 |
Why?
|
| Urologic Neoplasms | 1 | 2019 | 12 | 0.170 |
Why?
|
| Rabeprazole | 2 | 2013 | 2 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 2 | 2011 | 747 | 0.120 |
Why?
|
| Esomeprazole | 1 | 2013 | 1 | 0.110 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2013 | 10 | 0.110 |
Why?
|
| Streptococcus bovis | 1 | 2013 | 3 | 0.110 |
Why?
|
| Diverticulosis, Colonic | 1 | 2013 | 2 | 0.110 |
Why?
|
| Ticlopidine | 1 | 2013 | 47 | 0.110 |
Why?
|
| Endocarditis, Bacterial | 1 | 2013 | 30 | 0.110 |
Why?
|
| Streptococcal Infections | 1 | 2013 | 77 | 0.100 |
Why?
|
| Duodenal Diseases | 1 | 2012 | 17 | 0.100 |
Why?
|
| Hepatic Artery | 1 | 2012 | 22 | 0.100 |
Why?
|
| Popliteal Artery | 1 | 2012 | 25 | 0.100 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2012 | 12 | 0.100 |
Why?
|
| Leg | 1 | 2012 | 86 | 0.100 |
Why?
|
| Constipation | 1 | 2012 | 17 | 0.100 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2012 | 67 | 0.100 |
Why?
|
| Benzamides | 1 | 2012 | 61 | 0.100 |
Why?
|
| Morpholines | 1 | 2012 | 85 | 0.100 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2012 | 86 | 0.100 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2012 | 103 | 0.100 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2013 | 218 | 0.090 |
Why?
|
| Bone and Bones | 1 | 2012 | 159 | 0.090 |
Why?
|
| Helicobacter Infections | 1 | 2011 | 56 | 0.090 |
Why?
|
| Helicobacter pylori | 1 | 2011 | 59 | 0.090 |
Why?
|
| Spiramycin | 1 | 2011 | 1 | 0.090 |
Why?
|
| Antiprotozoal Agents | 1 | 2011 | 8 | 0.090 |
Why?
|
| Metronidazole | 1 | 2011 | 7 | 0.090 |
Why?
|
| Lebanon | 1 | 2010 | 10 | 0.090 |
Why?
|
| Receptors, Cholecystokinin | 1 | 2010 | 2 | 0.090 |
Why?
|
| Receptors, Guanylate Cyclase-Coupled | 1 | 2010 | 3 | 0.090 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2010 | 9 | 0.090 |
Why?
|
| Choledocholithiasis | 1 | 2010 | 5 | 0.090 |
Why?
|
| Receptors, Opioid | 1 | 2010 | 14 | 0.090 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 1 | 2010 | 24 | 0.090 |
Why?
|
| Nerve Growth Factors | 1 | 2010 | 26 | 0.090 |
Why?
|
| Amines | 1 | 2010 | 30 | 0.090 |
Why?
|
| Ischemia | 1 | 2012 | 195 | 0.090 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2011 | 41 | 0.090 |
Why?
|
| Neurotransmitter Agents | 1 | 2010 | 41 | 0.090 |
Why?
|
| Melatonin | 1 | 2010 | 66 | 0.090 |
Why?
|
| Alcohol Drinking | 1 | 2013 | 306 | 0.090 |
Why?
|
| Humans | 14 | 2019 | 60912 | 0.090 |
Why?
|
| Enzymes | 1 | 2010 | 33 | 0.090 |
Why?
|
| Haplotypes | 1 | 2010 | 122 | 0.090 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 265 | 0.090 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2010 | 78 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2010 | 120 | 0.080 |
Why?
|
| Abdominal Pain | 1 | 2010 | 97 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 1060 | 0.080 |
Why?
|
| Embolization, Therapeutic | 1 | 2012 | 309 | 0.080 |
Why?
|
| Male | 11 | 2013 | 28424 | 0.080 |
Why?
|
| Calcium | 1 | 2012 | 560 | 0.080 |
Why?
|
| Narcotic Antagonists | 1 | 2010 | 116 | 0.080 |
Why?
|
| Liver Diseases | 1 | 2010 | 139 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 478 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 701 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 703 | 0.070 |
Why?
|
| Liver | 1 | 2010 | 800 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2012 | 5347 | 0.060 |
Why?
|
| Female | 7 | 2013 | 31706 | 0.050 |
Why?
|
| Colonoscopy | 2 | 2013 | 104 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2013 | 3188 | 0.050 |
Why?
|
| Adult | 6 | 2012 | 16211 | 0.040 |
Why?
|
| Middle Aged | 5 | 2013 | 16857 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 484 | 0.030 |
Why?
|
| Aged | 4 | 2013 | 13873 | 0.030 |
Why?
|
| Intestinal Polyps | 1 | 2013 | 7 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2C19 | 1 | 2013 | 7 | 0.030 |
Why?
|
| Platelet Aggregation | 1 | 2013 | 27 | 0.030 |
Why?
|
| Hematemesis | 1 | 2012 | 5 | 0.030 |
Why?
|
| Heartburn | 1 | 2012 | 3 | 0.030 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2012 | 16 | 0.030 |
Why?
|
| Collagen Type I | 1 | 2012 | 38 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2012 | 28 | 0.030 |
Why?
|
| Parathyroid Hormone | 1 | 2012 | 43 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 195 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2013 | 476 | 0.030 |
Why?
|
| Angiography | 1 | 2012 | 145 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2013 | 101 | 0.020 |
Why?
|
| Bacteremia | 1 | 2013 | 92 | 0.020 |
Why?
|
| Intermittent Claudication | 1 | 2012 | 50 | 0.020 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2011 | 4 | 0.020 |
Why?
|
| Amoxicillin | 1 | 2011 | 7 | 0.020 |
Why?
|
| Clarithromycin | 1 | 2011 | 6 | 0.020 |
Why?
|
| Gastritis | 1 | 2011 | 17 | 0.020 |
Why?
|
| Adolescent | 2 | 2012 | 6041 | 0.020 |
Why?
|
| Linear Models | 1 | 2012 | 432 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 593 | 0.020 |
Why?
|
| Genotype | 1 | 2013 | 652 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 292 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2011 | 156 | 0.020 |
Why?
|
| Acute Disease | 1 | 2012 | 672 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2013 | 1088 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 465 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 462 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 1271 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 830 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 1321 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 1548 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 2011 | 208 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2011 | 756 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2013 | 2517 | 0.020 |
Why?
|
| Biomarkers | 1 | 2012 | 1346 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 2544 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 1518 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 2642 | 0.010 |
Why?
|
| Risk Factors | 1 | 2013 | 5158 | 0.010 |
Why?
|
| Time Factors | 1 | 2010 | 3661 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 4430 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2010 | 6192 | 0.010 |
Why?
|